Patents by Inventor Mark E. Fraley

Mark E. Fraley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mineralocorticoid receptor modulators
    Patent number: 8063090
    Abstract: The present invention relates to diphenylmethyl imidazole mineralocorticoid receptor modulators compounds having the structure and their use in treating cardiovascular events.
    Type: Grant
    Filed: March 19, 2008
    Date of Patent: November 22, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Philip E. Brandish, James C. Hershey, Mark E. Fraley, Justin T. Steen
  • Disubstituted Azepan Orexin Receptor Antagonists
    Publication number: 20110207715
    Abstract: The present invention is directed to disubstituted azepan and oxazepan amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: October 15, 2009
    Publication date: August 25, 2011
    Inventors: Christopher D. Cox, Mark E. Fraley, John D. Schreier
  • Pyridine carboxamide orexin receptor antagonists
    Patent number: 8003797
    Abstract: The present invention is directed to pyridyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: August 23, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jeffrey M. Bergman, Paul J. Coleman, Mark E. Fraley, Swati P. Mercer, Thomas S. Reger, Anthony J. Roecker, Justin T. Steen
  • AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA
    Publication number: 20110160229
    Abstract: The present invention is directed to AHCY inhibitors of formula (I): which are useful in the treatment of diseases characterized by high homocysteine levels, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases characterized by high homocysteine levels.
    Type: Application
    Filed: August 31, 2009
    Publication date: June 30, 2011
    Inventors: Antonella Converso, Timothy J. Hartingh, Mark E. Fraley
  • OXAZOLOBENZIMIDAZOLE DERIVATIVES
    Publication number: 20110124661
    Abstract: The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Application
    Filed: May 8, 2009
    Publication date: May 26, 2011
    Inventors: Edward J. Brnardic, Antonella Converso, Mark E. Fraley, Robert M. Garbaccio, Shaei Y. Huang
  • OXAZOLOBENZIMIDAZOLE DERIVATIVES
    Publication number: 20110065669
    Abstract: The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Application
    Filed: May 8, 2009
    Publication date: March 17, 2011
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Edward J. Brnardic, Mark E. Fraley, Robert M. Garbaccio
  • AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA
    Publication number: 20100305135
    Abstract: The present invention is directed to AHCY inhibitors of formula (I) which are useful in the treatment of diseases characterized by high homocysteine levels, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases characterized by high homocysteine levels.
    Type: Application
    Filed: February 18, 2009
    Publication date: December 2, 2010
    Applicant: MERCK & CO., INC.
    Inventors: Robert M. Garbaccio, Antonella Converso, Mark E. Fraley, Timothy J. Hartingh
  • MINERALOCORTICOID RECEPTOR MODULATORS
    Publication number: 20100261765
    Abstract: The present invention relates to dihydropyridine mineralocorticoid receptor modulating compounds having the structure: and their use in treating cardiovascular events.
    Type: Application
    Filed: December 10, 2008
    Publication date: October 14, 2010
    Inventors: Philip E. Brandish, Mark E. Fraley, James C. Hershey, Justin T. Steen
  • PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20100197652
    Abstract: The present invention is directed to pyridyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: August 7, 2008
    Publication date: August 5, 2010
    Inventors: Jeffrey M. Bergman, Paul J. Coleman, Mark E. Fraley, Swati P. Mercer, Thomas S. Reger, Anthony J. Roecker, Justin T. Steen
  • Mitotic kinesin inhibitors
    Patent number: 7732472
    Abstract: The present invention relates to dihydroisoxazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: June 8, 2010
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Corp.
    Inventors: Mark E. Fraley, Robert M. Garbaccio, George D. Hartman
  • Mitotic kinesin inhibitors
    Patent number: 7723365
    Abstract: The present invention relates to oxadiazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: May 25, 2010
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Corp.
    Inventors: Christopher D. Cox, Mark E. Fraley, Robert M. Garbaccio
  • MINERALOCORTICOID RECEPTOR MODULATORS
    Publication number: 20100069452
    Abstract: The present invention relates to diphenylmethyl imidazole mineralocorticoid receptor modulators compounds having the structure and their use in treating cardiovascular events.
    Type: Application
    Filed: March 19, 2008
    Publication date: March 18, 2010
    Inventors: Philip E. Brandish, James C. Hershey, Mark E. Fraley, Justin T. Steen
  • Mitotic kinesin inhibitors
    Patent number: 7632833
    Abstract: The present invention relates to tricyclic pyrazoles according to Formula (I) that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: December 15, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Jeffrey M. Bergman, Paul J. Coleman, Mark E. Fraley, Robert M. Garbaccio, George D. Hartman, Chunze Li, Lou Anne Neilson, Christy M. Olson, Edward S. Tasber
  • Mitotic kinesin inhibitors
    Patent number: 7625912
    Abstract: The present invention relates to 2-phenylpyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: December 1, 2009
    Assignee: Merck & Co. Inc
    Inventors: Kenneth L. Arrington, Mark E. Fraley, George D. Hartman
  • Mitotic kinesin inhibitors
    Patent number: 7622468
    Abstract: The present invention relates to tetrahydropyridine compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: December 16, 2003
    Date of Patent: November 24, 2009
    Assignee: Merck & Co. Inc.
    Inventors: Mark E. Fraley, Robert M. Garbaccio
  • Mitotic kinesin inhibitors
    Patent number: 7622489
    Abstract: The present invention relates to tetrahydropyridine compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: December 16, 2003
    Date of Patent: November 24, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Robert M. Garbaccio, Christy M. Olson, Edward S. Tasber
  • Mitotic kinesin inhibitors
    Patent number: 7618971
    Abstract: The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: November 17, 2009
    Assignee: Merck & Co. Inc.
    Inventors: Paul J. Coleman, Christopher D. Cox, Mark E. Fraley, George D. Hartman, John Schreier
  • Inhibitors of Checkpoint Kinases
    Publication number: 20090258852
    Abstract: The instant invention provides for compounds which comprise benzoisoquinolinones and aza derivatives that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: June 30, 2006
    Publication date: October 15, 2009
    Inventors: Kenneth L. Arrington, Vadim Y. Dudkin, Mark E. Fraley, Robert M. Garbaccio, George D. Hartman, Shaei Y. Huang, Constantine Kreatsoulas, Edward S. Tasber
  • Inhibitors of checkpoint kinases
    Publication number: 20090233896
    Abstract: The instant invention provides for compounds which comprise substituted pyridyl aminothiazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: June 5, 2006
    Publication date: September 17, 2009
    Inventors: Kenneth L. Arrington, Vadim Y. Dudkin, Mark E. Fraley, Jacob M. Hoffman, Constantine Kreatsoulas, Cheng Wang
  • Inhibitors of checkpoint kinases
    Publication number: 20090182001
    Abstract: The instant invention provides for compounds which comprise fused imidazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: July 18, 2006
    Publication date: July 16, 2009
    Inventors: Mark E. Fraley, Justin T. Steen